The Controlled Antenatal Thyroid Screening (CATS) study investigated treatment of suboptimal gestational thyroid function (SGTF) on childhood cognition and found no difference in intelligence quotient (IQ) at 3 years between children of treated and untreated SGTF mothers. We have measured IQ in the same children at age 9.5 years and included children from normal gestational thyroid function (normal-GTF) mothers.
T ri-iodothyronine and thyroxine (T4) are essential for early brain development, and maternal thyroid hormones are required by the fetus until its own thyroid starts to function, which can be as late as 18 weeks gestation (1) (2) (3) . Before this, thyroid hormones in the fetal brain are solely of maternal origin (4, 5) . Thyroid dysfunction occurs in ;2.5% of pregnancies (6) , and severe hypothyroidism during the first two trimesters may result in irreversible neurologic deficits, although the effect of more modest variation in thyroid hormone levels is unclear. Later in pregnancy, the fetus may be better able to compensate for any lack of maternal thyroid hormones, but compensation is likely to be incomplete until the fetal thyroid is fully functional at term (7) .
Several studies reported that higher levels of maternal thyroid-stimulating hormone (TSH) during pregnancy may be associated with a negative impact on the child's intelligence (8) (9) (10) (11) , but this was not confirmed by others (12, 13) . Likewise, findings for low maternal thyroxine levels are contradictory with some (9, (13) (14) (15) (16) (17) but not all (10, (18) (19) (20) (21) studies, providing evidence of lowered intelligence in the children. As well as intelligence quotient (IQ) and general cognition, further deficits for offspring following exposure to underactive maternal thyroid function have been identified, including memory (15, (22) (23) (24) (25) and motor difficulties (8, 9, 16, 26, 27) , among others.
The Controlled Antenatal Thyroid Screening (CATS) study commenced in 2002 (CATS-I) and was the first randomized controlled trial (RCT) to investigate the effect of screening and treatment of hypothyroidism during pregnancy on child cognition (28) . Women (n = 21,846) were recruited at a median gestation of 12 weeks, 3 days [in 10 centers in United Kingdom (UK) and 1 center in Turin, Italy]. Mothers were defined as having suboptimal gestational thyroid function (SGTF) if their free thyroxine (FT4) was ,2.5th percentile, and/or TSH was .97.5th percentile, as assessed during the CATS study, and onehalf was treated with 150 mg levothyroxine (LT4) daily. Offspring born to mothers with SGTF had their IQ assessed at age 3 years, and no difference was found between those whose mothers were treated (mean IQ 99.2) or untreated (100.0) during pregnancy (P = 0.40). Similar results were obtained in a recent study from Casey et al. (29) , who reported no beneficial effect on offspring cognition up to age 5 of treating mothers with subclinical hypothyroidism or hypothyroxinemia at 16.7 or 17.8 weeks mean gestation, respectively. The young age of the children, when tested in these large RCTs, might explain the reported lack of treatment effect. IQ evaluations below age 5 may serve as a general indicator of cognitive function but may not be best suited as a longer-term measure of cognitive function (30) . Therefore, the primary aim of CATS II was to measure the children's cognitive function at age 9 years using a more in-depth battery of tests. Furthermore, neither of these trials compared the IQs of children from euthyroid mothers with those of mothers with SGTF to elucidate whether there is a deficit requiring treatment. Our second aim addressed this point by assessing cognitive function in children from mothers with normal gestational thyroid function (normal-GTF). The dose of LT4 used in the CATS study was relatively high, and recent reports suggest adverse effects of cognition from both too much and too little thyroid hormone (31) . Consequently, we explored a possible effect of "overtreatment" (defined as maternal FT4 above the 97.5th percentile of the CATS-I UK cohort) on IQ scores. Finally, we analyzed the correlation between cognitive assessments undertaken at age 3 and 9 years, as this will be invaluable when designing future studies.
Methods

Study design and population
The original CATS study was previously described in detail (28) . In brief, CATS-I recruited 21,846 women (excluding history of thyroid disease, twin pregnancies, maternal age ,18 years, or gestational age . 15 weeks and 6 days), predominantly in the UK, at their first antenatal hospital appointment. Participants were randomized either to screen (treated) or control (untreated) groups, the former having their thyroid function tested immediately, and the latter after their child was born. If the mother's FT4 was ,2.5th percentile, and/or TSH was .97.5th percentile, then they were classified as having SGTF, with percentiles calculated from the CATS cohort. Women in the screen group with SGTF were treated with LT4 (starting dosage 150 mg) for the remainder of their pregnancies. The primary outcome was children's IQ at age 3 from the screen and control groups.
CATS-II included only UK participants for logistical reasons (n = 16,346). The target sample size was informed by prior power calculations (see later in text). All CATS mothers from the UK SGTF-treated and SGTF-untreated groups (n = 609) were invited to participate by letter. The Welsh Demographics Service and Patient Data Registrar provided current addresses. Those without SGTF in the control and screen branches of the RCT were pooled (UK n = 15,737) and named "normal-GTF"; a random sample of 4000 from this group was also invited to participate, again by letter (Fig. 1) .
Cognitive assessments
CATS-II IQ and additional cognitive assessments were conducted when children were aged 7.00 to 10.92 years (32) , either in the research center or in their homes. One psychologist (C. Hales) undertook all of the CATS-II assessments to allow good consistency and was unaware of the participant group. Ten percent of assessments were double scored (by R. Paradice) to ensure accuracy (32) . IQ was measured using the Wechsler Intelligence Scale for Children, Fourth Edition UK (WISC-IV), which generated a full-scale IQ (FSIQ), calculated equally from four subdomains: verbal comprehension IQ (VCIQ), perceptual reasoning IQ (PRIQ), working memory IQ (WMIQ), and processing speed IQ (PSIQ). Additional cognitive assessments (8, 22) were administered to some children (those not too tired following WISC administration), using the Developmental Neuropsychological Assessment (NEPSY), Second Edition (details can be found in the Supplemental Information). These assessments tested long-term memory [memory for designs (MD) delayed and list memory (LM)], working memory (MD and narrative memory), and fine-motor coordination (fingertip-tapping dominant hand and fingertip-tapping nondominant hand). As the normal-GTF group means for both assessments were close to the anticipated values (WISC-IV IQ: 100; additional NEPSY assessments: 10), the authors conclude that there was no selection bias in which children completed all assessments in CATS-II.
CATS-II was approved by the Wales Research Ethics Committee 2 (reference no. 10/WSE03/33) and Cardiff and Vale University Health Board. Written and informed consent was obtained from all mothers, both in CATS-II and initially during their pregnancies; child assent was obtained during the research center visits. Missing data were largely a result of nonresponse to invitation.
Sample-size justification
Samples of 120 participants from the treated (CATS-I screen) and untreated SGTF (CATS-I control) groups would have 90% power to detect a difference of six points in mean IQ or 80% power with a 5% two-sided significance level to detect a 1.97 Figure 1 . Flow chart of recruitment to the CATS study illustrates initial recruitment for CATS-I, when child IQ was assessed at 3 years of age, and the follow-up study, CATS-II, in which child IQ was assessed at 9 years of age. WISC-IV, Wechsler Intelligence Scale for Children, Fourth Edition UK. doi: 10.1210/jc.2017-02378 https://academic.oup.com/jcemincrease in odds of IQ , 85 in untreated SGTF, assuming the mean IQ is 100 with a standard deviation (SD) of 15 (32) . Participants (240; 1.5%) from the normal-GTF group (CATS-I normal thyroid function in test and screen groups) were required to assess whether maternal SGTF influenced their children's IQ.
Analyses
The data were analyzed in SPSS, version 20, and STATA, version 12, in accordance with the prespecified statistical plan (32) .
The primary analysis assessed the odds of FSIQ , 85 in the normal-GTF and the merged SGTF group. An interaction term for treatment of SGTF was then added, all using logistic regression. Mean IQ differences and percentages with FSIQ , 85 were also compared among the three groups. Univariate analysis was followed by multivariate analysis of covariates (MANCOVA) to adjust for key potential covariates in the following four models: Step-wise analysis of covariates was performed only for binary outcomes, but all six covariates were included in continuous analyses.
Secondary analyses explored several aspects. We assessed using likelihood ratio tests, whether response to treatment best fitted a proportional or nonproportional model. With the use of the normal-GTF to the untreated SGTF data, we could investigate whether maternal TSH influenced FSIQ.
We also compared subdomain IQs (VCIQ, PRIQ, WMIQ, and PSIQ) in the treated and untreated SGTF groups to explore the effect of treatment, initially, by logistic regressions for scores ,85 and then a MANCOVA adjusted for the six covariates for mean scores. The additional cognitive assessments were also compared by a MANCOVA and an analysis of covariance for the LM subtest (reduced dataset as a result of late introduction).
Sensitivity analyses comprised comparison of CATS-I and CATS-II VCIQ, PRIQ, and FSIQs using Pearson correlations.
As exploratory analyses, within the broad term of SGTF, we investigated subclinical hypothyroidism (FT4 . 2.5th and TSH . 97.5th percentiles), isolated hypothyroxinemia (FT4 , 2.5th and TSH , 97.5th percentiles), and overt hypothyroidism (FT4 , 2.5th and TSH . 97.5th percentiles). These were calculated by MANCOVAs (IQs, additional cognitive assessments, and LM) to include interactions among the three groups, normal-GTF, and whether maternal SGTF was treated.
Finally, we explored differences among participants, taking account of those we defined as "overtreated," i.e., the treated SGTF group whose FT4 values were above the 17.7-pmol/L threshold established by the 97.5th percentile at recruitment in the UK CATS sample. We compared oversupplementation with child FSIQ , 85 first, followed by analyses for mean scores, all adjusted for the same covariates detailed previously.
Supplemental exploratory analyses can be found in the Supplemental Information: subclinical hypothyroidism, isolated hypothyroxinemia, and overt hypothyroidism.
Results
Group characteristics
In CATS-I, 16,346 women were UK-based and provided the prospective cohort for CATS-II. There were 382 treated and 371 untreated for SGTF; of these, 303 treated and 306 untreated SGTF offspring completed IQ testing at age 3.2 years. No data were collected from the normal-GTF group.
In CATS-II, IQ assessment occurred in a total of 449 children at a mean age of 9.5 years: 119 treated SGTF, 98 untreated SGTF, and 232 from the normal-GTF group (Fig. 1) . Smaller groups completed the additional cognitive assessments (see Supplemental Data for explanations): 110 treated SGTF, 85 untreated SGTF, and 215 normal-GTF.
At recruitment into CATS-I, CATS-II mothers from normal-GTF, treated, and untreated SGTF groups had median TSHs of 1.16, 4.09, and 3.57 mU/L, respectively, and mean FT4s were 14.12, 11.92, and 11.79 pmol/L, respectively ( Table 1 ). The CATS-I and CATS-II SGTF samples were largely unbiased (statistics presented in Supplemental Table 1 ).
Significant differences among the CATS-II participant groups are detailed in Table 1 . As anticipated, maternal FT4 and TSH, at recruitment into CATS-I, were higher (FT4) and lower (TSH) in the normal-GTF compared with both SGTF groups. Maternal TSH was higher in the treated compared with untreated SGTF CATS-II mothers. Mean maternal age at consent into CATS-I was higher in the normal-GTF compared with the treated SGTF group, although only by 0.8 year. Likewise, a difference between the groups was seen in those from the SGTF groups, being more likely to opt for participation from their home rather than attending the research clinic. The children in the normal-GTF group were significantly older (by just 4 months) than the SGTF groups.
Primary analysis
There was no significant difference for odds of FSIQ , 85 between the normal-GTF and merged SGTF groups Table 2 displays the FSIQ regression models.
The percentages with IQ , 85 were 6.03% in normal-GTF, 7.56% in treated, and 11.22% in untreated SGTF groups (Table 3 ; x P for the trend = 0.11).
Secondary analyses
Do data fit a proportional or nonproportional model?
Mean child FSIQs per group were 103.10 (SD 11.68), 101.76 (12.04), and 102.31 (13.27) for the normal-GTF, treated, and untreated SGTF groups, respectively (Table 3) . There was no difference among the mean FSIQ scores of the three participant groups (P = 0.678). There was no significant difference for odds of the normal-GTF children having higher 
Does treatment of SGTF affect any subdomain?
No differences were found among subdomain IQ scores , 85 (see Table 2 for sub-IQ regression models) or for mean subdomain IQ scores for VCIQ, PRIQ, WMIQ, and PSIQ among the groups (P = 0.193). The mean scores of the additional cognitive assessments were also compared, with no difference identified among the three participant groups (P = 0.732, LM P = 0.266; Table 3 ).
Sensitivity analysis
As CATS-II followed the UK sample, we analyzed the CATS-I UK-only cohort (n = 609) and revealed IQ , 85 in 14% treated and 17% untreated; the difference was not significant. Furthermore, there was no significant difference in percentage IQ , 85 treated vs untreated in the CATS-II subset of CATS-I (n = 212).
Pearson correlations to assess how associated the scores were from the Wechsler Preschool and Primary Scale of Intelligence, Third Edition, and the WISC-IV for the treated and untreated SGTF groups found that all scores were positively correlated (P , 0.0001). Furthermore, age 3 IQ predicts 45% of the variation in age 9 IQ with other variables, such as breastfeeding contributing only an additional 1%.
Exploratory analyses
Different types of abnormal thyroid function (subclinical hypothyroidism, isolated hypothyroxinema) were also explored using MANCOVA. No significant differences were found in the mean IQ scores (IQ , 85) or additional assessments between children of treated and untreated mothers. Similar results were obtained in the offspring of a small number of women with overt hypothyroidism, identified during participation in CATS, although IQ , 85 was apparent in 0% of the treated but 10% of the untreated groups. These analyses are presented in Supplemental Table 2 .
Oversupplementation Finally, we explored differences among participants, taking account of those in the treated SGTF group with raised FT4 values [20 We compared oversupplementation with child FSIQ , 85 first, followed by analyses for mean scores, all adjusted for the same covariates detailed previously. There was no significant effect on a child's IQ , 85 and no difference among mean IQ scores of the groups or additional cognitive assessments, including the LM subtest (P = 0.875, P = 0.765, and P = 0.951, respectively; data not shown).
Of note, we observed no detrimental effect of oversupplementation on IQ , 85 in children of such women in CATS-I for whom we had information on FT4 levels after therapy was initiated (UK cohort, n = 609).
Discussion
We revisited the effects of treatment of SGTF on cognition in the CATS children at an average age of 9.5 years. Our results confirm those of CATS-I, in that we saw no significant differences in FSIQ , 85 or mean IQ scores in the children of treated and untreated women. Our results also confirm those of Casey and colleagues (29) , who reported no beneficial effect on offspring cognition up to age 5 of treating mothers with subclinical hypothyroidism or hypothyroxinemia at 16.7 or 17.8 weeks mean gestation, respectively. Of interest Haddow et al. (8) reported that mean FSIQ scores and FSIQ scores , 85 were not significantly different in comparing children born to mothers who were treated or not (P = 0.20 and P = 0.90, respectively), although the study was retrospective, and the treatment groups were small. In contrast to our findings, however, the study by Haddow et al. (8) showed that the IQ of children born to untreated mothers was significantly lower than those of control children.
One criticism of CATS-I was that cognitive assessments were conducted in children at too young an age for differences to be evident Our current findings indicate that this may not be the case, as we found that IQ scores at ages 3 and 9 were strongly correlated in the two CATS studies with FSIQ at age 3, predicting 45% of the variability in FSIQ at age 9 and with other factors contributing very little.
The design of the CATS-I study has also been questioned in relation to the timing of initiation of LT4 therapy. The fetus relies wholly on maternal T4 delivery, up until ;14 to 18 weeks gestation, when its own thyroid gland becomes functional (7) . Fetal brain development begins immediately after conception and, therefore, treatment initiated at 12 to 13 weeks may have missed the early, critical phase of brain development. The CATS study participants were recruited during their first scheduled visit to the antenatal clinic, which generally fell toward the end of the first trimester (median of 12 weeks and 3 days) (33) . Likewise, LT4 supplementation in the study by Casey et al. (29) was started even later, and thus, future trials would benefit from recruiting women at a much earlier stage of pregnancy to overcome these limitations.
A further consideration in the CATS study design is that the starting dose of LT4 administered may have been too high, and therefore, adverse outcomes in women who were overtreated may have masked any benefits of treatment. The CATS-I study was the first RCT to investigate the effects of treatment of SGTF in pregnancy, and hence, there were no previous studies for guidance. Furthermore, there is no universal consensus on T4 supplementation dose, even for the treatment of women with overt hypothyroidism who become pregnant. Of note, guidelines for the management of thyroid function during pregnancy recommend assay of TSH alone, and indeed, treatment in CATS-I was monitored and adjusted based on TSH levels. As a result, approximately one-third of the treated mothers achieved a high FT4, which was accompanied by a switch from a positive correlation between FT4 and age 9 cognition at recruitment to a negative correlation after treatment (Supplemental Information). However, in contrast to a study illustrating a biphasic effect of FT4 on cognition, with children of women with both low and high FT4 levels displaying lower IQs and smaller gray matter and cortex volumes (31), we observed no significant difference in the proportion of IQ , 85 at age 9 in children of overtreated mothers compared with the rest. Furthermore, we did not find any detrimental effect on IQ , 85 in children of such women when we analyzed the age 3 cognition data in CATS-I (UK-only cohort).
CATS-II included children from normal-GTF women and found no difference in IQ measures between these and children from SGTF mothers, whether treated or not. This confirmed previous studies reporting no effect of low thyroid function on offspring intelligence or cognition (10, 12, 13, (18) (19) (20) (21) and may, to some extent, explain the absence of treatment benefits observed in the trial. However, our results contradict many animal studies, possibly because the thyroid abnormalities in the CATS mothers are mild when compared with models induced, e.g., by thyroidectomy. The lack of agreement on the effects of FT4 on cognition in observational studies is the result of varying definitions of SGTF, the lack of universal pregnancy-specific reference ranges for thyroid function tests, and the application of various tools to measure cognition in children across the age spectrum. Hence, it is not surprising that the benefits of universal screening during pregnancy on cognition remain hotly debated, although other adverse pregnancy outcomes have been well reported (such as pre-eclampsia, miscarriage, and preterm birth) (34) (35) (36) . In our protocol paper (32) , one of the secondary analyses planned to investigate whether the combination of low maternal FT4 during pregnancy and the presence of an adverse deiodinase 2 genotype in her child would impact cognition. The hypothesis followed reports that Thr92Ala reduced conversion of T4 to triiodothyronine (37) . We genotyped 426 CATS children, finding 73 alanine homozygotes; when a mother had low FT4 during pregnancy, and the child had the homozygous alanine deiodinase 2 genotype, treatment appeared to reduce the odds of FSIQ , 85 (reduced OR from 5.72 to 1.85), although this was nonsignificant and included only a small number of the participants (data not shown).
Our study has some limitations, although throughout all analyses, adjustments were made to control for extraneous effects. The CATS-II power calculation was based on an IQ difference of six points, as found by Haddow et al. (8) in offspring of women with overt hypothyroidism. We studied women with less severe thyroid dysfunction, and thus, the study may have been underpowered to detect more subtle cognitive variation. This was exacerbated by the recruitment challenges that we faced from the outset-the main problem was a result of participants having relocated since participating in CATS-I and not responding to invitation. As the study developed, the recruitment process evolved, and rates improved, but the extension of the data-collection period would have taken the children closer to puberty and its complications. There were some differences noted among the three groups, raising the possibility of bias. However, significantly older normal-GTF children than those from the SGTF groups should not have affected the results, as both assessment tools used have scores age corrected in 3-month intervals. Likewise, differences in maternal age at recruitment and place of child assessment were both covariates controlled for in the analyses.
In conclusion, results obtained in the current follow-up study have shown no effect of LT4 supplementation in women with SGTF on child IQ at age 9. These findings support those of the original CATS-I study and a recent large RCT. Our data are consistent with the lack of treatment effect being a result of the similar proportion of IQ , 85 in children of normal-GTF and SGTF mothers, rather than the age of cognitive assessment or the relatively high dose of LT4 supplementation. However, future large, randomized trials, with LT4 interventions at a much earlier stage of pregnancy (or preconception), may still be warranted, as the benefits of treatment may not be fully realized unless treatment is commenced early.
